We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques.
- Authors
Camargos, Vidyleison N.; Rossi, Shannan L.; Juelich, Terry L.; Smith, Jennifer K.; Vasilakis, Nikos; Freiberg, Alexander N.; Nichols, Rick; Fusco, Joan
- Abstract
Filoviruses, like the Marburg (MARV) and Ebola (EBOV) viruses, have caused outbreaks associated with significant hemorrhagic morbidity and high fatality rates. Vaccines offer one of the best countermeasures for fatal infection, but to date only the EBOV vaccine has received FDA licensure. Given the limited cross protection between the EBOV vaccine and Marburg hemorrhagic fever (MHF), we analyzed the protective efficacy of a similar vaccine, rVSV-MARV, in the lethal cynomolgus macaque model. NHPs vaccinated with a single dose (as little as 1.6 × 107 pfu) of rVSV-MARV seroconverted to MARV G-protein prior to challenge on day 42. Vaccinemia was measured in all vaccinated primates, self-resolved by day 14 post vaccination. Importantly, all vaccinated NHPs survived lethal MARV challenge, and showed no significant alterations in key markers of morbid disease, including clinical signs, and certain hematological and clinical chemistry parameters. Further, apart from one primate (from which tissues were not collected and no causal link was established), no pathology associated with Marburg disease was observed in vaccinated animals. Taken together, rVSV-MARV is a safe and efficacious vaccine against MHF in cynomolgus macaques.
- Subjects
VESICULAR stomatitis; MARBURG virus; HEMORRHAGIC fever; VACCINE effectiveness; DEATH rate
- Publication
Viruses (1999-4915), 2024, Vol 16, Issue 8, p1181
- ISSN
1999-4915
- Publication type
Article
- DOI
10.3390/v16081181